QUEBEC CITY, QUEBEC — OCTOBER 10, 2007 — Advitech Inc. (“Advitech” or the “Corporation”) (TSX Venture Exchange: AVI) today announced that two milk-derived protein extracts from its XP-828L technological platform have demonstrated wound-healing properties in an in vivo study conducted by Dr. Charles Doillon of the Oncology and Molecular Endocrinology Research Centre at the Centre Hospitalier de l’Université Laval (CHUL). Dr. Doillon is a recognized researcher in the field of wound healing and angiogenesis. The study has demonstrated that both protein extracts could significantly impact the wound-healing response, especially the formation of regenerated collagen fibre and its remodelling in wound tissue.
“The data further confirms the bio-activity of our protein extracts and brings new opportunities for Advitech. The results suggest that these two products act early in the healing process and would accelerate wound-healing without excessive long-term remodelling”, stated Dr. Christina Juneau, Vice-President, Research and Development. “Three potential fields of application have been identified”, added Dr. Juneau:
1. The management of skin ulcers, particularly pressure ulcers;
2. The improvement of scar tissue response in plastic and reconstructive surgery and dermabrasion;
3. The acceleration of the healing process in burn wounds.
“Part of our 2007 business plan focuses on the identification of new commercial opportunities targeting dermatological applications, with additional revenues for the 2008 fiscal year”, stated Renaud Beauchesne, president and CEO at Advitech. “With these positive results regarding wound-healing applications, we have achieved an additional milestone in our plan, while developing our natural growth factor based technological platform with respect to natural growth factors”, commented Mr. Beauchesne.
According to Espicom Business Intelligence Ltd., the global wound care market totalled $7.2 billion in 2006, with a 10% growth rate. Growth factor based applications for wound-healing represent more than 5% of the market, with an impressive 27% growth rate.
About Advitech Inc. www.advitech.com
Advitech is a health sciences and technology company with a mission to discover and commercialize proprietary and evidence-based natural health products. Effective and safe, these products play a role in the prevention of Immune-mediated inflammatory disorders, such as psoriasis and inflammatory bowel disease. Recently, Advitech launched Dermylex™ for the treatment of mild-to-moderate psoriasis.
About Dermylex™ www.dermylex.com
Dermylex™, developed by Advitech, is an oral natural health product formulated to improve mild-to-moderate psoriasis symptoms. Two clinical trials, including a 112-day, multi-center, double-blind, placebo-controlled trial with 84 patients, clinically proved the efficacy and safety of Dermylex™ for that type of psoriasis. Dermylex™ is currently available in Canada and the U.S. (as BioDerm, Dermylex), and will soon be available in France and Belgium (as Psopax).
This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.